Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways... Show more
A.I.dvisor tells us that NXTS and BIOX have been poorly correlated (+5% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NXTS and BIOX's prices will move in lockstep.
| Ticker / NAME | Correlation To NXTS | 1D Price Change % | ||
|---|---|---|---|---|
| NXTS | 100% | -9.21% | ||
| BIOX - NXTS | 5% Poorly correlated | +3.84% | ||
| CF - NXTS | 3% Poorly correlated | -2.41% | ||
| SEED - NXTS | 2% Poorly correlated | +0.08% | ||
| ICL - NXTS | -0% Poorly correlated | -0.22% | ||
| CTVA - NXTS | -3% Poorly correlated | +2.41% | ||
More | ||||
| Ticker / NAME | Correlation To NXTS | 1D Price Change % |
|---|---|---|
| NXTS | 100% | -9.21% |
| Chemicals: Agricultural industry (13 stocks) | 10% Poorly correlated | -1.55% |
| Process Industries industry (164 stocks) | 8% Poorly correlated | +0.14% |
Industry ChemicalsAgricultural
It is expected that a price bounce should occur soon.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for NXTS just turned positive on October 27, 2026. Looking at past instances where NXTS's MACD turned positive, the stock continued to rise in 36 of 43 cases over the following month. The odds of a continued upward trend are 84%.
Following a +8.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where NXTS advanced for three days, in 159 of 189 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
NXTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NXTS as a result. In 91 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NXTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NXTS entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.405) is normal, around the industry mean (-0.403). P/E Ratio (0.029) is within average values for comparable stocks, (8.767). NXTS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.867). Dividend Yield (0.000) settles around the average of (0.126) among similar stocks. NXTS's P/S Ratio (4.315) is very high in comparison to the industry average of (1.476).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. NXTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NXTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.